Eikon announced itself in 2021 with former Merck & Co. exec Roger Perlmutter, M.D., Ph.D., at the helm and quickly ...

Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care ...

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to ...

Full abstracts will be released on February 4, 2026, at 7:00 am CET/1:00 am EST and will be available via the conference website here .

Innovative Molecules GmbH, a German clinical stage biotech company focused on development of novel agents in the field of ...

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

Every time a cell divides, it must copy its entire genome so that each daughter cell inherits a complete set of DNA. During that process, enzymes known as polymerases race along the DNA to copy its ...

The helicase domain of Dicer-2 independently activates an unidentified signaling pathway to induce Vago protein expression, which is involved in antiviral host defense. Dicer-2-mediated gene ...

Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.

The South San Francisco start-up is offering 17.6 million shares at a price range of $16 to $18, which would give the company ...

The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.